Cover Image
市場調查報告書

PharmaPoint:急性冠狀動脈症候群 (ACS) - 全球醫藥品的預測與市場分析

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

出版商 GlobalData 商品編碼 318323
出版日期 內容資訊 英文 416 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:急性冠狀動脈症候群 (ACS) - 全球醫藥品的預測與市場分析 PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025
出版日期: 2016年08月08日 內容資訊: 英文 416 Pages
簡介

本報告提供急性冠狀動脈症候群 (ACS) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 分類或病期分類系統
  • 症狀
  • 預後
  • QOL

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
    • ACS和確診的患者數
    • ACS和確診的患者數:各年齡
    • ACS和確診的患者數:性別
    • ACS和確診的患者數:各疾病 (STEMI,NSTEMI,UA)
    • ACS與確診的患者數:年齡調整
    • ACS的住院患者數
    • ACS的住院患者數:性別
    • ACS的住院患者數:各疾病 (STEMI,NSTEMI,UA)
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
  • 美國
  • EU5個國家
  • 日本

第6章 競爭評估

  • 概要
  • 產品簡介:ACS

第7章 未滿足需求和機會

第8章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物

第9章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Amgen
    • AstraZeneca
    • Bristol-Myers Squibb
    • Cerenis Therapeutics
    • CSL Limited
    • 第一三共
    • Eli Lilly
    • Esperion Therapeutics
    • GlaxoSmithKline
    • Janssen
    • The Medicines Company
    • Merck & Co.
    • Pfizer
    • Sanofi

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC131PIDR

Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality in the world. The term acute coronary syndrome (ACS) applies to a spectrum of acute CVD states that are precipitated by coronary artery occlusion (stenosis) that results in ischemia (a reduction or loss of blood flow to tissue) and the necrosis of myocardial tissue .In the most modern use of the term, ACS strictly refers to a range of ischemic cardiovascular events that includes unstable angina (UA), myocardial infarction (MI) and/or death due to myocardial ischemia. In general, these ACS events can be viewed as the culmination of coronary artery disease (CAD), the asymptomatic build-up of atherosclerotic plaque on the walls of the coronary arteries. The triggering of an ACS event stemming from UA or MI initiates the acute phase treatment setting where therapeutic interventions are utilized to reverse and prevent the physiochemical processes that lead to coronary stenosis. Whereas, the chronic phase treatment setting involves secondary preventative measures that are used to avoid recurrent ACS events from occurring.

Highlights

Key Questions Answered

  • The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?
  • The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases , as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?

Key Findings

  • The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
  • The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.
  • The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
  • The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.

Scope

  • Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global ACS therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification or Staging Systems
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. ACS Diagnosed Prevalence
    • 4.3.2. STEMI and NSTEMI Trends
    • 4.3.3. ACS Hospitalizations
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for ACS (2015-2025)
    • 4.5.1. Diagnosed Prevalent Cases of ACS
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of ACS
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of ACS
    • 4.5.4. Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA
    • 4.5.5. Age-Standardized Diagnosed Prevalence of ACS
    • 4.5.6. ACS Hospitalizations
    • 4.5.7. Sex-Specific ACS Hospitalizations
    • 4.5.8. ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Acute Coronary Syndrome
    • 6.2.1. Antihypertensives
    • 6.2.2. Anticoagulants
    • 6.2.3. Fibrinolytics
    • 6.2.4. Antidyslipidemics
    • 6.2.5. Antiplatelets

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Management of ACS in Elderly Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Blood Thinning Agent with Reduced Bleeding
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Achieving Guideline-Recommended Levels of LDL-C
    • 7.5.1. Unmet need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Optimal Treatment of ACS Patients with Hyperglycemia
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Bococizumab
    • 8.2.2. Anacetrapib
    • 8.2.3. CSL-112
    • 8.2.4. CER-001
    • 8.2.5. LY3015014
    • 8.2.6. AMG-899
    • 8.2.7. ETC-1002

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Amgen
    • 9.3.2. AstraZeneca
    • 9.3.3. Bristol-Myers Squibb
    • 9.3.4. Cerenis Therapeutics
    • 9.3.5. CSL Limited
    • 9.3.6. Daiichi Sankyo
    • 9.3.7. Eli Lilly
    • 9.3.8. Esperion Therapeutics
    • 9.3.9. GlaxoSmithKline
    • 9.3.10. Janssen
    • 9.3.11. The Medicines Company
    • 9.3.12. Merck & Co.
    • 9.3.13. Pfizer
    • 9.3.14. Sanofi

10. Market Outlook

  • 10.1. Global Market
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Acute Coronary Syndrome Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Analyst
    • 11.6.2. Therapy Area Director
    • 11.6.3. Epidemiologist
    • 11.6.4. Global Director of Therapy and Epidemiology
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Marketed Antiplatelet Agents that Inhibit Platelet Activation
  • Table 2: Marketed Anticoagulants that Inhibit the Coagulatory Cascade
  • Table 3: Antidyslipidemic agents
  • Table 4: Classifications of ACS
  • Table 5: Universal Classification of MI
  • Table 6: Symptoms of Acute Coronary Syndrome
  • Table 7: Risk Factors and Comorbidities for ACS
  • Table 8: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants
  • Table 9: 7MM, Sources of Diagnosed Prevalence Data for MI
  • Table 10: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI
  • Table 11: 7MM, Data Sources of ACS Hospitalizations
  • Table 12: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations
  • Table 13: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Table 14: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015
  • Table 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N (Row %), 2015
  • Table 16: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages ≥25 Years, N (Row %), 2015
  • Table 17: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Table 18: 7MM, Sex-Specific ACS Hospitalizations, Ages ≥25 Years, N (Row %), 2015
  • Table 19: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages ≥25 Years, Both Sexes, N, 2015
  • Table 20: Most-Prescribed Drugs for ACS by Class in the Global Markets, 2015
  • Table 21: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
  • Table 22: Country Profile for ACS - US
  • Table 23: Country Profile for ACS - 5EU
  • Table 24: Country Profile for ACS - Japan
  • Table 25: Leading Treatments for ACS, 2015
  • Table 26: Commonly Used Beta Blockers
  • Table 27: Product Profile - Beta Blockers
  • Table 28: Beta Blockers SWOT Analysis, 2015
  • Table 29: Global ACS Sales Forecasts [$m] for Beta Blockers, 2015-2025
  • Table 30: Commonly Used ACE Inhibitors
  • Table 31: Product Profile - ACE Inhibitors
  • Table 32: ACE Inhibitor-SWOT Analysis, 2015
  • Table 33 Global ACS Sales Forecasts [$m] for ACE inhibitors, 2015-2025
  • Table 34: Commonly Used ARBs
  • Table 35: Product Profile - Angiotensin Receptor Blockers (ARBs)
  • Table 36: ARB SWOT Analysis, 2015
  • Table 37: Global ACS Sales Forecasts [$m] for ARBs, 2015-2025
  • Table 38: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs)
  • Table 39: MRA SWOT Analysis, 2016
  • Table 40: Global ACS Sales Forecasts [$m] for MRAs, 2015-2025
  • Table 41: Product Profile - Warfarin
  • Table 42: Warfarin SWOT Analysis, 2015
  • Table 43: Global ACS Sales Forecasts [$m] for Warfarin, 2015-2025
  • Table 44: Product Profile - Angiomax
  • Table 45: AngiomaxSWOT Analysis, 2015
  • Table 46: Global ACS Sales Forecasts [$m] for Angiomax, 2015-2025
  • Table 47: Product Profile - Fondaparinux
  • Table 48: Arixtra SWOT Analysis, 2015
  • Table 49: Global ACS Sales Forecasts ($M) for Fondaparinux, 2015-2025
  • Table 50: Product Profile - Xarelto (rivaroxaban)
  • Table 51: Xarelto SWOT Analysis, 2015
  • Table 52: Global ACS Sales Forecast ($M) for Xarelto, 2015-2025
  • Table 53: Commonly Used tPAs
  • Table 54: Product Profile - Tissue Plasminogen Activator (tPA)
  • Table 55: Fibrinolytics-SWOT Analysis, 2015
  • Table 56: Global ACS Sales Forecast ($M) for Fibrinolytics, 2015-2025
  • Table 57: Product Profile - Repatha (Evolocumab)
  • Table 58: Product Profile - Praluent (Alirocumab)
  • Table 59: PCSK9 inhibitors SWOT Analysis, 2015
  • Table 60: Global ACS Sales Forecasts [$m] for Repatha, 2015-2025
  • Table 61: Global ACS Sales Forecasts [$m] for Praluent, 2015-2025
  • Table 62: Product Profile - Atorvastatin
  • Table 63: Product Profile - Simvastatin
  • Table 64: Lipitor (Atorvastatin) SWOT Analysis, 2015
  • Table 65: Zocor (Simvastatin) SWOT Analysis, 2015
  • Table 66: Global ACS Sales Forecasts [$m] for Generic Statins, 2015-2025
  • Table 67: Product Profile - Crestor (Rosuvastatin)
  • Table 68: Crestor (Rosuvastatin) SWOT Analysis, 2015
  • Table 69: Global ACS Sales Forecasts [$m] for Crestor, 2015-2025
  • Table 70: Product Profile - Clopidogrel
  • Table 71: Clopidogrel SWOT Analysis, 2015
  • Table 72: Global ACS Acute Phase Sales Forecast ($M) for Clopidogrel, 2015-2025
  • Table 73: Global ACS Chronic Phase Sales Forecasts ($M) for Clopidogrel, 2015-2025
  • Table 74: Product Profile - Brilinta (ticagrelor)
  • Table 75: Brilinta (ticagrelor) SWOT Analysis, 2015
  • Table 76: Global Acute Phase ACS Sales Forecast ($M) for Brilinta, 2015-2025
  • Table 77: Global ACS Chronic Phase Sales Forecast ($M) for Brilinta, 2015-2025
  • Table 78: Product Profile - Effient (Prasugrel)
  • Table 79: Effient (Prasugrel) SWOT Analysis, 2015
  • Table 80: Global Acute Phase ACS Sales Forecast ($M) for Effient, 2015-2025
  • Table 81: Global ACS Chronic Phase Sales Forecast ($M) for Effient, 2015-2025
  • Table 82: Product Profile - Integrilin (Eptifibatide)
  • Table 83: Integrilin (Eptifibatide) SWOT Analysis, 2015
  • Table 84: Global ACS Sales Forecast ($M) for Integrilin, 2015-2025
  • Table 85: Product Profile - Cangrelor
  • Table 86: Kengreal (cangrelor) SWOT Analysis, 2015
  • Table 87: Global ACS Sales Forecasts ($M) for Kengreal, 2015-2025
  • Table 88: Product Profile - Zontivity (Vorapaxar)
  • Table 89: Vorapaxar SWOT Analysis, 2015
  • Table 90: Global ACS Sales Forecast ($M) for Zontivity, 2015-2025
  • Table 91: Unmet Need and Opportunity in ACS
  • Table 92: Comparison of Therapeutic Classes in Development for ACS, 2015
  • Table 93: Comparison of Therapeutic Classes in Pipeline for ACS, 2016
  • Table 94: Product Profile - Bococizumab (PF-04950615)
  • Table 95: Bococizumab (PF-04950615) SWOT Analysis, 2015
  • Table 96: Global ACS Sales Forecasts [$m] for Bococizumab, 2015-2025
  • Table 97: Product Profile - Anacetrapib
  • Table 98: Anacetrapib SWOT Analysis, 2015
  • Table 99: Global ACS Sales Forecasts [$m] for Anacetrapib, 2015-2025
  • Table 100: Product Profile - CSL-112
  • Table 101: CSL-112 SWOT Analysis, 2015
  • Table 102: Global ACS Sales Forecasts [$m] for CSL-112, 2015-2025
  • Table 103: Product Profile - CER-001
  • Table 104: CER-001 SWOT Analysis, 2015
  • Table 105: Global ACS Sales Forecasts [$m] for CER-001, 2015-2025
  • Table 106: Product Profile - LY3015014
  • Table 107: LY3015014 SWOT Analysis, 2015
  • Table 108 Global ACS Sales Forecasts [$m] for LY3015014 , 2015-2025
  • Table 109: Product Profile - AMG-899
  • Table 110: AMG-899 SWOT Analysis, 2015
  • Table 111: Global ACS Sales Forecasts [$m] for AMG-899, 2015-2025
  • Table 112: Product Profile - ETC-1002
  • Table 113: ETC-1002 SWOT Analysis, 2016
  • Table 114: Global ACS Sales Forecasts [$m] for ETC-1002, 2015-2025
  • Table 115: Key Companies in the ACS Market, 2016
  • Table 116: Amgen's ACS Portfolio Assessment, 2016
  • Table 117: AstraZeneca's ACS Portfolio Assessment, 2015
  • Table 118: BMS's ACS Portfolio Assessment, 2015
  • Table 119: Cerenis' ACS Portfolio Assessment, 2015
  • Table 120: CSL Limited's ACS Portfolio Assessment, 2015
  • Table 121: Daiichi Sankyo's ACS Portfolio Assessment, 2015
  • Table 122: Eli Lilly's ACS Portfolio Assessment, 2015
  • Table 123: Esperion's ACS Portfolio Assessment, 2016
  • Table 124: GlaxoSmithKline's Acute Coronary Syndrome Portfolio Assessment, 2015
  • Table 125: Janssen's ACS Portfolio Assessment, 2015
  • Table 126: The Medicines Company's Acute Coronary Syndrome Portfolio Assessment, 2015
  • Table 127: Merck's ACS Portfolio Assessment, 2015
  • Table 128: Pfizer's ACS Portfolio Assessment, 2015
  • Table 129: Sanofi's ACS Portfolio Assessment, 2015
  • Table 130: Global Sales Forecasts [$m] for Acute Coronary Syndrome, 2015-2025
  • Table 131: ACS Global market - Drivers and Barriers, 2015-2025
  • Table 132: Sales Forecasts [$m] for Acute Coronary Syndrome in the US, 2015-2025
  • Table 133: Key Events Impacting Sales for ACS in the US, 2015-2025
  • Table 134: US ACS Market - Drivers and Barriers, 2015-2025
  • Table 135: Sales Forecasts [$m] for Acute Coronary Syndrome in France, 2015-2025
  • Table 136: Key Events Impacting Sales for ACS in France, 2015-2025
  • Table 137: France ACS market - Drivers and Barriers, 2015-2025
  • Table 138: Sales Forecasts [$m] for Acute Coronary Syndrome in Germany, 2015-2025
  • Table 139: Key Events Impacting Sales for ACS in Germany, 2015-2025
  • Table 140: Germany ACS market - Drivers and Barriers, 2015-2025
  • Table 141: Sales Forecasts [$m] for Acute Coronary Syndrome in Italy, 2015-2025
  • Table 142: Key Events Impacting Sales for ACS in Italy, 2015-2025
  • Table 143: Italy ACS market - Drivers and Barriers, 2015-2025
  • Table 144: Sales Forecasts [$m] for Acute Coronary Syndrome in Spain, 2015-2025
  • Table 145: Key Events Impacting Sales for ACS in Spain, 2015-2025
  • Table 146: Spain ACS Market - Drivers and Barriers, 2015-2025
  • Table 147: Sales Forecasts [$m] for Acute Coronary Syndrome in the UK, 2015-2025
  • Table 148: Key Events Impacting Sales for ACS in the UK, 2015-2025
  • Table 149: UK ACS market - Drivers and Barriers, 2015-2025
  • Table 150: Sales Forecasts [$m] for Acute Coronary Syndrome in Japan, 2015-2025
  • Table 151: Key Events Impacting Sales for ACS in Japan, 2015-2025
  • Table 152: Japan ACS Market - Drivers and Barriers, 2015-2025
  • Table 153: Key ACS Launch Dates
  • Table 154: Key Patent Expiries
  • Table 155: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
  • Figure 2: Progression of CAD, Atherosclerotic Plaque Rupture, Thrombosis, and ACS
  • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
  • Figure 4: Electrocardiography in the Diagnosis of ACS
  • Figure 5: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990-2008
  • Figure 6: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%)
  • Figure 7: Case Segmentation Map
  • Figure 8: 7MM, Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Figure 9; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015
  • Figure 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages ≥25 Years, N, 2015
  • Figure 11: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages ≥25 Years, N, 2015
  • Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages ≥25 Years, 2015
  • Figure 13: 7MM ACS Hospitalizations, Ages ≥25 Years, Both Sexes, N, Select Years, 2015-2025
  • Figure 14: 7MM, Sex-Specific ACS, Ages ≥25 Years, N, 2015
  • Figure 15: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages ≥25 Years, Both Sexes, N, 2015
  • Figure 16: Company Portfolio Gap Analysis in ACS, 2015-2025
  • Figure 17: Global Sales for ACS by Region, 2015-2025
  • Figure 18: Global Sales for ACS by Class, 2015-2025
  • Figure 19 Global Sales for PCSK9 inhibitors for ACS, 2015-2025
  • Figure 20: Sales for ACS in the US by Drug Class, 2015-2025
  • Figure 21: Sales for ACS in France by Drug Class, 2015-2025
  • Figure 22: Sales for ACS in Germany by Drug Class, 2015-2025
  • Figure 23: Sales for ACS in Italy by Drug Class, 2015-2025
  • Figure 24: Sales for ACS in Spain by Drug Class, 2015-2025
  • Figure 25: Sales for ACS in the UK by Drug Class, 2015-2025
  • Figure 26: Sales for ACS in Japan by Drug Class, 2015-2025
Back to Top